Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price traded down 0.3% during trading on Monday . The company traded as low as $10.50 and last traded at $10.89, with a volume of 157,294 shares traded. The stock had previously closed at $10.86.

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 28th. Piper Jaffray Cos. reiterated a “buy” rating and set a $27.00 price target (up previously from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Finally, Gabelli assumed coverage on Collegium Pharmaceutical in a report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $27.60.

The stock has a 50 day moving average price of $10.57 and a 200 day moving average price of $14.52. The stock’s market capitalization is $247.75 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.29. On average, equities analysts expect that Collegium Pharmaceutical Inc. will post ($3.86) EPS for the current year.

In related news, Director John A. Fallon bought 2,375 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were purchased at an average price of $10.59 per share, with a total value of $25,151.25. Following the purchase, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 37.93% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its stake in shares of Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,665 shares during the last quarter. Alliancebernstein L.P. bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth $122,000. Royal Bank of Canada raised its stake in shares of Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth $143,000. Finally, A.R.T. Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth $148,000. 62.13% of the stock is currently owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.